Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »